SCHEMBL29403247

SCHEMBL29403247

O=[N+]([O-])c1ccc(Cl)c(S(=O)(=O)Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
KMT2A Q03164 2/20 0.60
MEN1 O00255 1/20 0.60
HSD17B10 Q99714 1/20 0.60
RAB9A P51151 1/20 0.52
TDP1 Q9NUW8 2/20 0.51
VCAM1 P19320 1/20 0.50
ALOX5 P09917 1/20 0.50
NHERF1 O14745 1/20 0.49
MCL1 Q07820 1/20 0.49
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
GPR55 Q9Y2T6 1/20 0.48
PDE2A O00408 1/20 0.46
PDE5A O76074 1/20 0.46
CYP3A4 P08684 1/20 0.46
ALOX15 P16050 1/20 0.46
NFKB1 P19838 1/20 0.46
APEX1 P27695 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL452351 1.00 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2KMT2AMEN1HSD17B10
SCHEMBL10453008 0.87 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2KMT2AMEN1HSD17B10
SCHEMBL10453009 0.87 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2KMT2AMEN1HSD17B10
SCHEMBL1817485 0.85 HSD17B10 (0.60) ALDH1A1SMN1; SMN2KMT2AMEN1HSD17B10
SCHEMBL31518627 0.85 HSD17B10 (0.60) ALDH1A1SMN1; SMN2KMT2AMEN1HSD17B10
SCHEMBL5075923 0.84 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2KMT2AMEN1HSD17B10
SCHEMBL9838827 0.84 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2KMT2AMEN1HSD17B10
SCHEMBL390493 0.84 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2KMT2AMEN1HSD17B10
SCHEMBL2483870 0.84 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2KMT2AMEN1HSD17B10
SCHEMBL7769137 0.84 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2KMT2AMEN1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3966208-A2 COMPOUNDS AND METHODS FOR TREATING CANCER Antidote IP Holdings, LLC (US) 2022-03-16 EP disclosed